



Forward Looking Statements

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS •

The information that follows is as of January 1, 2018 or such earlier date indicated herein. The Company assumes no obligation to update forward-looking statements contained in these or any other materials as a result of new information or future events or developments.

This information contains forward-looking information about the Company's financial results and estimates, business plans and prospects, products and product candidates, and other information that involves substantial risks and uncertainties. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "target," "forecast" and other words and terms of similar meaning or use future dates in connection with any discussion of future operating or financial performance or business plans and prospects. The factors that could cause actual results to differ materially include, without limitation, the following: our ability to raise capital to continue as a going concern, our limited operating history, our ability to execute the business model, our ability to profitably commercialize our products, our ability to timely and cost effectively build required manufacturing facilities, product liability claims, adverse economic conditions, our ability to enter into definitive agreements with key strategic collaborators, changes in governmental regulations or other laws, medical reimbursement policies, our ability to protect our intellectual property rights, changes to demands in our products due to competitive developments or changes in scientific information, our ability to retain the services of key scientific and business personnel and other factors.

New factors may emerge from time to time, and it is not possible for management to predict all of such factors. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

MEDOLAC[®]

A Public Benefit Corporation

Using scale and disruptive technology to make human milk accessible to all hospitalized babies in need






Each year 300,000 preterm babies are born in the US

Without human milk feeding at least **2,300** infants die from a preventable death (NEC) at an average cost of **\$14.5M/baby**

Thousands more die of sepsis

Research is driving increased demand by hospitals

Research Proves Human Milk Reduces NEC/Sepsis



- 50% fatal
- Survivors lose up to 80% of gut
- Cost of one NEC death= \$14.5M




So, why don't mothers provide their milk?

- 70% do, but preemies need 4x more protein
- And preemies need higher calories
- Mothers often have trouble supplying milk
- Or have their own medical problems

Does Medolac replace mother's milk?

- No, mother's milk is combined with our products to raise protein and calories and supply the volume needed
- Or can be used without mother's milk



How Does Medolac Solve the Problem?

What we do

Collect and process enormous volumes of human milk to make milk more affordable and end the practice of rationing in hospitals

Who is the customer?

We sell to primarily to hospitals

Why don't all preterm babies receive human milk?

All other sources are frozen, expensive and scarce
Overnight shipping, nursing time and waste doubles the cost of use

Billion dollar US market

- ✓ \$1 billion potential US market
- ✓ Only 1 competitor (frozen)
- ✓ Products are safer and more convenient
- ✓ 3 Year Shelf Life
- ✓ High volume processing has lowered the COGS



New Facility for Rapid Expansion

50,000 sf facility in Boulder City, NV
Capable of processing 1,000 gal/day
Supporting revenue to \$500M



American Red Cross



Economics

- *\$9 million raised to date*
- *Trailing revenues of \$1.5M (growing to \$5M within 12 mos)*
- *Profitability within 12 months*
- *Projected revenue of \$500M by 2021*
- *Average GM of 80% at half of the competitor price*
- *Exit/liquidity event expected in 3-4 years*
- *\$5M Note offering convertible to upcoming C round with 40% discount upon conversion (\$3.8M raised)*

MEDOLAC[®]

A PUBLIC BENEFIT CORPORATION

Contact us

Elena Medo direct: 949-375-4116

Company phone: 1-866-599-7740

Web: www.medolac.com

Email: emedo@medolac.com